These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34258160)

  • 1. A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules.
    Liu QX; Zhou D; Han TC; Lu X; Hou B; Li MY; Yang GX; Li QY; Pei ZH; Hong YY; Zhang YX; Chen WZ; Zheng H; He J; Dai JG
    Adv Sci (Weinh); 2021 Jul; 8(13):2100104. PubMed ID: 34258160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
    BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
    Schotten LM; Darwiche K; Seweryn M; Yildiz V; Kneuertz PJ; Eberhardt WEE; Eisenmann S; Welter S; Sisson BE; Pietrzak M; Wiesweg M; Ploenes T; Hager T; He K; Freitag L; Aigner C; Taube C; Oezkan F
    Eur J Cancer; 2021 Apr; 147():142-150. PubMed ID: 33662689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNF213 gene mutation in circulating tumor DNA detected by targeted next-generation sequencing in the assisted discrimination of early-stage lung cancer from pulmonary nodules.
    Jiang N; Zhou J; Zhang W; Li P; Liu Y; Shi H; Zhang C; Wang Y; Zhou C; Peng C; Zhang W; Hao Y; Sun Q; Li Y; Zhao X
    Thorac Cancer; 2021 Jan; 12(2):181-193. PubMed ID: 33200540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA).
    Liang W; Zhao Y; Huang W; Gao Y; Xu W; Tao J; Yang M; Li L; Ping W; Shen H; Fu X; Chen Z; Laird PW; Cai X; Fan JB; He J
    Theranostics; 2019; 9(7):2056-2070. PubMed ID: 31037156
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
    Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
    Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
    Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
    JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of conventional tumor markers in young patients with pulmonary nodules.
    Xu L; Su Z; Xie B
    J Clin Lab Anal; 2021 Sep; 35(9):e23912. PubMed ID: 34296781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction model for malignant pulmonary nodules based on cfMeDIP-seq and machine learning.
    Qi J; Hong B; Tao R; Sun R; Zhang H; Zhang X; Ji J; Wang S; Liu Y; Deng Q; Wang H; Zhao D; Nie J
    Cancer Sci; 2021 Sep; 112(9):3918-3923. PubMed ID: 34251068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test.
    Liang W; Chen Z; Li C; Liu J; Tao J; Liu X; Zhao D; Yin W; Chen H; Cheng C; Yu F; Zhang C; Liu L; Tian H; Cai K; Liu X; Wang Z; Xu N; Dong Q; Chen L; Yang Y; Zhi X; Li H; Tu X; Cai X; Jiang Z; Ji H; Mo L; Wang J; Fan JB; He J
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33793424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Establishment and Verification of A Novel Predictive Model of Malignancy
for Non-solid Pulmonary Nodules].
    Xiao F; Yu Q; Zhang Z; Liu D; Liang C
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):26-33. PubMed ID: 30674390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of models for predicting the probability of malignancy in patients with pulmonary nodules.
    Li Y; Hu H; Wu Z; Yan G; Wu T; Liu S; Chen W; Lu Z
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32068231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a multiprotein plasma classifier to identify benign lung nodules.
    Vachani A; Pass HI; Rom WN; Midthun DE; Edell ES; Laviolette M; Li XJ; Fong PY; Hunsucker SW; Hayward C; Mazzone PJ; Madtes DK; Miller YE; Walker MG; Shi J; Kearney P; Fang KC; Massion PP
    J Thorac Oncol; 2015 Apr; 10(4):629-37. PubMed ID: 25590604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and validation of multiclassification prediction models for pulmonary nodules based on machine learning.
    Liu Q; Lv X; Zhou D; Yu N; Hong Y; Zeng Y
    Clin Respir J; 2024 May; 18(5):e13769. PubMed ID: 38736274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules.
    Johnson MK; Wu S; Pankratz DG; Fedorowicz G; Anderson J; Ding J; Wong M; Cao M; Babiarz J; Lofaro L; Walsh PS; Kennedy GC; Huang J
    BMC Cancer; 2021 Apr; 21(1):400. PubMed ID: 33849470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localized thin-section CT with radiomics feature extraction and machine learning to classify early-detected pulmonary nodules from lung cancer screening.
    Tu SJ; Wang CW; Pan KT; Wu YC; Wu CT
    Phys Med Biol; 2018 Mar; 63(6):065005. PubMed ID: 29446758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.